Skip to content Skip to footer
Subscribe Now
EVENTS

Post Conference Highlights: Reuters Events Pharma Europe 2024

Knowledge-packed, informative, and engaging, the Reuters Pharma 2024 event brimmed with enlightening sessions, presentations, and scientific orators shedding light on innovative therapies and unmet needs of the healthcare sector.   Day 1 commenced with keynote speakers shedding light on next-generation customer engagement models, mastering patient-centric metrics, amplifying strategic voice, and expediting equitable access followed by a…
July 15, 2024

Read more

Viewpoints_Mina Makar
VIEWPOINTS

Inherited Retinal Disease Management: Brian Strem from Kiora Pharmaceuticals in a Stimulating Dialogue Exchange with PharmaShots

Shots:   Recently, Kiora Pharmaceuticals received an upfront payment of $16M after inking the partnership agreement with Théa Open Innovation to develop and commercialize KIO-301 and is eligible to receive up to $285M   KIO-301 belongs to a new-generation drug called molecular switches that offer a path around damaged receptors rather than looking to repair gene mutation  …
July 15, 2024

Read more

Viewpoints_Efrat Kaduri
VIEWPOINTS

Off the Shelf Platform: Efrat Kaduri from Pluri Inc. In a Riveting Conversation with PharmaShots

Shots:  Recently, Pluri launched its placental allogenic MAIT cell platform for immunotherapy treatment of solid tumors. Mucosal Associated Invariant T (MAIT) cells offer better advantages as compared to conventional T cells  Today, we have with us Efrat Kaduri shedding light on the potential of placental MAIT cells in treating solid tumors  While highlighting the intellectual…
July 10, 2024

Read more

ThoughtSpot_Saurabh Chaubey5
THOUGHTSPOT

4 Biopharma Trends to Watch out in 2024

Shots:  2023 had been a great year for the biopharma industry despite several imposed restrictions from the IRA and inflation  With several swaying factors impacting the biopharma industry, including social, economic, regulatory and others, some of the noteworthy trends that emerged in 2024 and are shaping the ways biopharma companies operate  The article explores four key…
July 9, 2024

Read more

Viewpoints_Xochitl Javier
VIEWPOINTS

Redefining Technology: Xochitl Javier from Thermo Fisher Scientific in Conversation with PharmaShots

Shots:  Raman Analyzers are widely used in the biopharma industry to analyze different substances. Based on the principles of Raman Spectroscopy, Raman Analyzers provide information about their chemical composition and structure when interacting with laser  Today, at PharmaShots, we have Xochitl Javier, Director, Product Management & Marketing, Thermo Fisher Scientific, shedding light on the TruScan…
July 8, 2024

Read more

Viewpoints_Andrew Menzies-Gow
VIEWPOINTS

AstraZeneca at ATS’24: Andrew Menzies-Gow from AstraZeneca in a Stimulating Conversation with PharmaShots

Shots:  AstraZeneca presented 59 abstracts, including 12 late-breaking posters at the American Thoracic Society, focussing on the unmet needs in COPD, EGPA, and other chronic respiratory diseases  Today, at PharmaShots, we have Andrew Menzies-Gow, sharing insights from the MANDARA study that evaluated Fasenra (benralizumab) for EGPA, a rare debilitating condition  Andrew stresses reducing the use…
July 3, 2024

Read more

Viewpoints_Jesse Mendelsohn
VIEWPOINTS

Drug Pricing & Rebate Management: Jesse Mendelsohn from Model N in Dialogue Exchange with PharmaShots

Shots:  Drug pricing reforms from the IRA continue to impact pharmaceutical companies. The rebates ensued from the IRA guidelines are heavily affecting the revenues of biopharma companies  Today, at PharmaShots we have Jesse Mendelsohn, Sr. Vice President at Model N shedding light on the company’s recently launched solution called Medicare Part D inflation rebate-per-unit  With…
July 1, 2024

Read more

VIEWPOINTS_Roy Maute_2024
VIEWPOINTS

Macrophage Checkpoint Therapy: Roy Maute from Pheast Therapeutics in a Riveting Conversation with PharmaShots

Shots:  Recently Pheast Therapeutics shared the preclinical data for PHST001, an anti-CD24 macrophage checkpoint inhibitor at the 20th Annual PEGS Boston Summit  Today, at PharmaShots, we had a dialogue exchange with Roy Maute, Cofounder and CEO of Pheast Therapeutics  Pheast Therapeutics currently plans to initiate a clinical trial in H1’25  Saurabh: Can you walk me…
June 26, 2024

Read more

VIEWPOINTS_Moitreyee Chatterjee-Kishore1_Kohei Shitara2_2024
VIEWPOINTS

Unlocking Approval: Moitreyee Chatterjee-Kishore from Astellas & Kohei Shitara in Conversation with PharmaShots

Shots:  East Asia and East Europe report significant incidences of Gastric Cancer. In 2022, Japan registered around 44,000 mortalities due to Gastric Cancer  VYLOY, an anti-claudin 18.2 (CLDN18.2) monoclonal antibody, received Japan’s approval in combination with chemotherapy for patients with HER2 -ve, CLDN18.2+ve, unresectable, advanced, or recurrent gastric cancer  Today, at PharmaShots we have Moitreyee…
June 24, 2024

Read more

Load more